Harmful Drugs Law
What is Bextra?
Bextra (Valdecoxib) is similar to Celebrex (Celecoxib) in the respect that it is a prescription COX-2 selective inhibitor nonsteroidal anti-inflammatory drug (NSAID) used for the relief of pain associated with osteoarthritis (OA), rheumatoid arthritis (RA) and menstrual cramps (primary dysmenorrhea). Bextra was manufactured by Pharmacia Corporation/Pfizer, Inc., and it was approved for these purposes by the Food and Drug Administration (FDA) on November 16, 2001. The marketing of Bextra started in March 2002.
Bextra, similar to Celebrex, works by inhibiting the COX-2 form of the COX enzyme to block production of prostaglandins. Prostaglandins are hormone-like substances that contribute to the symptoms of pain, fever and inflammation.
Bextra tablets for oral administration contain either 10 mg or 20 mg of the active ingredient, valdecoxib. Inactive ingredients include lactose monohydrate, microcrystalline cellulose, pregelatinized starch, croscarmellose sodium, magnesium stearate, hydroxypropyl methylcellulose, polyethylene glycol, polysorbate 80, and titanium dioxide.